Gilead Ends Late-Phase Ulcerative Colitis Study

October 4, 2016

Gilead Sciences halted its Phase II/III study evaluating the antibody GS-5745 for patients with active ulcerative colitis, after a planned interim analysis by a data monitoring committee found insufficient evidence of a treatment benefit. No safety concerns were noted.

A separate Phase III study of GS-5745 will continue in patients with gastric cancer, the company said, as well as a Phase II study in gastric cancer in combination with nivolumab, and additional Phase II studies in Crohn’s disease, rheumatoid arthritis and cystic fibrosis.

View today's stories